HER2 amplification has been demonstrated to be a poor prognostic indicator and oncogenic amplifications of HER2 have been reported in 20–30% of EAC cases as compared with just 3% in ESCC [12,61]. Here, ERBB2 is linked to esophageal squamous cell carcinoma.